• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Plerixafor as a preemptive or salvage therapy for healthy donors with poor mobilization of hematopoietic stem cells.

作者信息

Kuang Pu, Lin Ting, Chen Xinchuan, Yang Yunfan, Ji Jie, Dong Tian, Wang Jie, Li Yan, Niu Ting

机构信息

Department of Hematology, Institute of Hematology, West China Hospital of Sichuan University, Chengdu, PR China.

出版信息

Bone Marrow Transplant. 2022 Nov;57(11):1737-1739. doi: 10.1038/s41409-022-01789-1. Epub 2022 Sep 8.

DOI:10.1038/s41409-022-01789-1
PMID:36076012
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9630128/
Abstract
摘要

相似文献

1
Plerixafor as a preemptive or salvage therapy for healthy donors with poor mobilization of hematopoietic stem cells.普乐沙福作为造血干细胞动员不佳的健康供者的抢先或挽救性治疗。
Bone Marrow Transplant. 2022 Nov;57(11):1737-1739. doi: 10.1038/s41409-022-01789-1. Epub 2022 Sep 8.
2
The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor.按需添加培哚普利福（plerixafor）对粒细胞集落刺激因子动员的 CD34+造血细胞的 CXCR4 和黏附分子表达。
Transfusion. 2014 Sep;54(9):2325-35. doi: 10.1111/trf.12632. Epub 2014 Mar 28.
3
Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.培洛昔福联合粒细胞集落刺激因子与安慰剂联合粒细胞集落刺激因子动员多发性骨髓瘤且外周血 CD34+细胞计数低的患者中的 CD34+造血干细胞：一项随机试验的亚组分析结果。
Biol Blood Marrow Transplant. 2012 Oct;18(10):1564-72. doi: 10.1016/j.bbmt.2012.05.017. Epub 2012 Jun 6.
4
Accelerated lymphocyte reconstitution and long-term recovery after transplantation of lentiviral-transduced rhesus CD34+ cells mobilized by G-CSF and plerixafor.经 G-CSF 和 plerixafor 动员的慢病毒转导恒河猴 CD34+细胞移植后淋巴细胞快速重建和长期恢复。
Exp Hematol. 2011 Jul;39(7):795-805. doi: 10.1016/j.exphem.2011.04.002. Epub 2011 Apr 15.
5
Addition of plerixafor in poorly mobilized allogeneic stem cell donors.添加plerixafor 可改善动员不佳的异基因造血干细胞供者。
J Clin Apher. 2022 Aug;37(4):388-394. doi: 10.1002/jca.21992. Epub 2022 May 28.
6
Efficacy and safety of a reduced dose of plerixafor in combination with granulocyte colony-stimulating factor in healthy haploidentical stem cell donors.低剂量普勒昔伐联合粒细胞集落刺激因子在健康单倍体造血干细胞供者中的疗效和安全性。
Vox Sang. 2022 Jun;117(6):853-861. doi: 10.1111/vox.13266. Epub 2022 Mar 24.
7
Hematopoietic stem cell mobilization for gene therapy: superior mobilization by the combination of granulocyte-colony stimulating factor plus plerixafor in patients with β-thalassemia major.造血干细胞动员用于基因治疗：在重型β地中海贫血患者中，粒细胞集落刺激因子联合普乐沙福可实现更好的动员效果。
Hum Gene Ther. 2013 Oct;24(10):852-60. doi: 10.1089/hum.2013.163.
8
On demand plerixafor is safe and effective for hematopoietic progenitor cell mobilization in patients with light chain amyloidosis at risk for mobilization failure with G-CSF alone.对于单独使用粒细胞集落刺激因子（G-CSF）存在动员失败风险的轻链淀粉样变性患者，按需使用普乐沙福进行造血祖细胞动员是安全有效的。
Bone Marrow Transplant. 2023 May;58(5):610-612. doi: 10.1038/s41409-023-01938-0. Epub 2023 Feb 24.
9
[A Single-Center Analysis of the Use of G-CSF Combined with Plerixafor to Mobilize Peripheral Blood Hematopoietic Stem Cell from Healthy Related Donors in Allogeneic Hematopoietic Stem Cell Transplantation].[一项关于在异基因造血干细胞移植中使用粒细胞集落刺激因子（G-CSF）联合普乐沙福动员健康相关供者外周血造血干细胞的单中心分析]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022 Feb;30(1):286-291. doi: 10.19746/j.cnki.issn.1009-2137.2022.01.047.
10
Addition of plerixafor for CD34+ cell mobilization in six healthy stem cell donors ensured satisfactory grafts for transplantation.在六位健康的干细胞供者中添加普乐沙福以动员 CD34+ 细胞，确保了可接受的移植物用于移植。
Transfusion. 2014 Apr;54(4):1055-8. doi: 10.1111/trf.12383. Epub 2013 Aug 14.

引用本文的文献

1
Editorial: Mobilization of hematopoietic cells from the bone marrow to the peripheral blood: Challenges and new therapeutic targets.社论：造血细胞从骨髓向外周血的动员：挑战与新的治疗靶点
Front Pharmacol. 2025 Apr 22;16:1592559. doi: 10.3389/fphar.2025.1592559. eCollection 2025.

本文引用的文献

1
Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial.采用普乐沙福对动员效果不佳的异基因造血干细胞供者进行挽救性治疗：一项前瞻性Ⅱ期试验的结果。
Bone Marrow Transplant. 2021 Mar;56(3):635-645. doi: 10.1038/s41409-020-01053-4. Epub 2020 Oct 7.
2
Effect of high-dose plerixafor on CD34 cell mobilization in healthy stem cell donors: results of a randomized crossover trial.高剂量普乐沙福对健康干细胞供体CD34细胞动员的影响：一项随机交叉试验的结果
Haematologica. 2017 Mar;102(3):600-609. doi: 10.3324/haematol.2016.147132. Epub 2016 Oct 20.
3
International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium.急性移植物抗宿主病临床数据收集的国际多中心标准化：西奈山急性移植物抗宿主病国际联盟报告
Biol Blood Marrow Transplant. 2016 Jan;22(1):4-10. doi: 10.1016/j.bbmt.2015.09.001. Epub 2015 Sep 16.
4
Prediction of hematopoietic stem cell yield after mobilization with granulocyte-colony-stimulating factor in healthy unrelated donors.健康无关供者使用粒细胞集落刺激因子动员后造血干细胞产量的预测
Transfusion. 2015 Dec;55(12):2855-63. doi: 10.1111/trf.13239. Epub 2015 Jul 16.
5
The use of hematocrit level for predicting the efficiency of peripheral blood CD34(+) cell collection after G-CSF Mobilization in Healthy Donors.利用血细胞比容水平预测健康供者在粒细胞集落刺激因子动员后外周血CD34(+)细胞采集的效率。
J Clin Apher. 2015 Dec;30(6):329-34. doi: 10.1002/jca.21383. Epub 2015 Feb 7.
6
Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation.用于自体和异基因造血细胞移植的外周血祖细胞动员：美国血液和骨髓移植学会指南
Biol Blood Marrow Transplant. 2014 Sep;20(9):1262-73. doi: 10.1016/j.bbmt.2014.05.003. Epub 2014 May 9.
7
Peripheral blood CD34+ cell enumeration as a predictor of apheresis yield: an analysis of more than 1,000 collections.外周血 CD34+ 细胞计数作为单采产量的预测指标：对超过 1000 次采集的分析。
Biol Blood Marrow Transplant. 2012 May;18(5):763-72. doi: 10.1016/j.bbmt.2011.10.002. Epub 2012 Jan 3.
8
Allogeneic transplantation: peripheral blood vs. bone marrow.异基因移植：外周血与骨髓。
Curr Opin Oncol. 2012 Mar;24(2):191-6. doi: 10.1097/CCO.0b013e32834f5c27.
9
Best practice for peripheral blood progenitor cell mobilization and collection in adults and children: results of a Società Italiana Di Emaferesi e Manipolazione Cellulare (SIDEM) and Gruppo Italiano Trapianto Midollo Osseo (GITMO) consensus process.成人和儿童外周血造血祖细胞动员和采集的最佳实践：意大利细胞分离和处理协会（SIDEM）和意大利骨髓移植组（GITMO）共识过程的结果。
Transfusion. 2012 Apr;52(4):893-905. doi: 10.1111/j.1537-2995.2011.03385.x. Epub 2011 Oct 7.
10
Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.一项III期前瞻性随机双盲安慰剂对照试验，比较普乐沙福加粒细胞集落刺激因子与安慰剂加粒细胞集落刺激因子用于非霍奇金淋巴瘤患者自体干细胞动员和移植的效果
J Clin Oncol. 2009 Oct 1;27(28):4767-73. doi: 10.1200/JCO.2008.20.7209. Epub 2009 Aug 31.